AmbioPharm’s North Augusta expansion gains $118.96 million investment figure and end-2027 target

South Carolina’s Department of Commerce announced $118.96 million of investment and 202 planned jobs for AmbioPharm’s North Augusta expansion on June 16. Operations were expected to be online by the end of 2027.

The project involves a modular manufacturing building at the company’s existing campus at 1024 Dittman Court. Planned capabilities include solid-phase, liquid-phase and hybrid peptide synthesis, supported by semi-automated production systems and solvent-delivery infrastructure.

AmbioPharm had announced the expansion on March 24, describing 68,000 sq ft of purpose-built space for upstream commercial synthesis and large, complex peptide programs. June’s disclosure adds investment, employment and scheduling detail to that project; it is not a second expansion. The existing North Augusta operations are separate from the proposed new manufacturing space.

The state did not define “online” or provide a schedule for equipment qualification, validated production or customer-specific commercial batches. It also disclosed no reactor volumes or annual API output, so neither the investment nor floor area can be translated into peptide tonnage.

Sources

South Carolina Department of Commerce — North Augusta expansion disclosure

AmbioPharm — original expansion announcement, March 24, 2026